linjc16/ctgov huggingface dataset:
A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)

Study Overview
=================
Brief Summary
-----------------
The purpose of this focused registry is to evaluate the clinical implications of the RHP position (relative to the articulations) regarding functional and radiographic parameters in patients treated with the RHP with a straight and curved stem.

Official Title
-----------------
A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)

Conditions
-----------------
Fracture of the Radial Head Which is Not Amendable to an Adequate Osteosynthesis, Post-traumatic Deformity or Arthroses, Failed Open Reduction Internal Fixation (ORIF) of a Radial Head Fracture, Failed Conservative Radial Head Fracture Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Use of a short-or long-stemmed DePuy Synthes Radial Head Prosthesis due to any of the following indications: Fresh fracture of the radial head which is not amendable to an adequate -steosynthesis Post-traumatic deformity or arthroses Failed open reduction internal fixation (ORIF) Failed conservative radial head fracture treatment Informed consent obtained, i.e.: Ability to understand the content of the patient information / Informed Consent Form Willingness and ability to participate in the clinical investigation according to the Clinical Investigation Plan (CIP) Signed and dated Ethics Committee (EC) / Institutional Review Board (IRB) approved written informed consent Exclusion Criteria: Active infection at the affected elbow Any not medically managed severe systemic disease Pregnancy Prisoner Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the functional outcome | Elaborate if there is an association between the implant head and stem position (relative to the elbow articulations), functional outcomes and radiological parameters (radiolucency and arthritis) after 1 year in patients treated with a RHP | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of functional outcome | Elaborate if there is an association between the implant head and stem position (relative to the elbow articulations), functional outcomes and radiological parameters (radiolucency and arthritis) after 2 years | 24 months | 
| Range of motion | To investigate range of motion of the injured limb as compared to the contralateral side | 12 months | 
| Adverse events | To evaluate if the related adverse events have an effect on quality of life (EQ5D) | 12 months |
Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan

Study Overview
=================
Brief Summary
-----------------
Recent studies have demonstrated the promising potential that telehealth has in management of chronic disease. For COPD patients, implementation of telehealth reduced readmissions, emergency room visits, and exacerbations and was cost-effective. Telehealth as a method of delivering healthcare to remote, resource-deprived areas is not lacking in evidence of benefit; however, the situation about its more widespread use for monitoring purposes is much less clear. To date, most of the studies dealing with telehealth in COPD were conducted in countries covering vast territories. Therefore, it needs to be investigated whether telehealth conveys similar advantages for COPD patients in a small island country.

Official Title
-----------------
Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Other: Telehealth program
* Other: Usual care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admissions for chronic obstructive pulmonary disease Age 20 or more Exclusion Criteria: Discharge against medical advice Enrolled in other trials Not being discharged to home Unconsciousness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Telehealth program<br>Telehealth program service | Other: Telehealth program<br> <br> |
| Other: Usual care<br>Usual care service | Other: Usual care<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Hospital Readmission at 6 months |  | 6 months |
Exploring the Risk Factors for Colorectal Cancer in Our General Population Using Asian Pacific Screening Score: a Survey From Pakistan

Study Overview
=================
Brief Summary
-----------------
In Pakistan, due to the lack of a National based cancer registry exact number of CRC cases is unknown. However, minimal data that is present in literature shows an increase in CRC cases with a concerning increase in incidence in younger age groups11. This makes it pertinent to understand current pattern of CRC and its risk factors from a local perspective. This will direct future strategies in an attempt to reduce the incidence and mortality associated with CRC in our general population.

Official Title
-----------------
Exploring the Risk Factors for Colorectal Cancer in Our General Population Using Asian Pacific Screening Score: a Survey From Pakistan

Conditions
-----------------
Colorectal Cancer, Colorectal Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals visiting SIUT as attendants to the patients visiting outpatient department or admitted in hospital. Exclusion Criteria: Attendants / whose patients visit GI, colon and oncology OPD outpatient department or admitted in GI wards.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factor | evaluate internationally validated risk factors for colorectal cancer in our general population using a questionnaire based on the modified Asian Pacific Colorectal Screening score. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal carcinoma, Pakistan
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.

Official Title
-----------------
Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer

Conditions
-----------------
Adenocarcinoma

Intervention / Treatment
-----------------
* Drug: Epirubicin with Cyclophosphamide, followed by a Taxane
* Drug: Epirubicin with a Taxane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast Cancer Stage T1-3, N1, M0 Suitable candidate for anthracycline-containing adjuvant chemotherapy Exclusion Criteria: Evidence of residual tumor following surgery, or metastatic disease Received prior therapy for breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: B<br>ET (8 cycles) T = docetaxel or paclitaxel | Drug: Epirubicin with a Taxane<br>* Epirubicin = 75 mg/m2 per cycle Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2<br>* Other names: Epirubicin, ellence,;|
| Experimental: A<br>EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles T = docetaxel or paclitaxel | Drug: Epirubicin with Cyclophosphamide, followed by a Taxane<br>* Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2 Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2<br>* Other names: Epirubicin, ellence,;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease free survival at 3 years |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess safety in both treatment arms at 3 years |  | 3 years | 
| Compare overall survival between the 2 treatment arms at 3 years |  | 3 years |
Upper Limb Robotic Rehabilitation After Stroke

Study Overview
=================
Brief Summary
-----------------
This is a single arm study aimed at evaluating the acute effects induced by a single session of robot-assisted passive hand mobilization on local perfusion and upper limb function in post-stroke hemiparetic patients. Twenty-three participants with subacute or chronic stroke received 20 min passive mobilization of the paretic hand with robotic assistance. After the intervention, significant improvements were found in forearm perfusion, muscle tone significantly decreased and subjects reported decreased upper limb heaviness, stiffness and pain. This study supports novel evidence that hand robotic assistance promotes local forearm circulation, may help in the management of spasticity and acutely alleviates reported symptoms of heaviness, stiffness and pain in subjects with post-stroke hemiparesis.

Official Title
-----------------
Passive Mobilization With Robotic Assistance Improve Hemiparetic Upper Limb Circulation and Functional Status in Stroke Survivors.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Robotic passive mobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first event of cerebrovascular stroke; unilateral paresis; ability to remain in sitting position Exclusion Criteria: bilateral impairment; cognitive or behaviorql dysfunctions; finger flexion contracture; degenerative or non degenerative neurological conditions; refusal or inability to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Passive mobilization<br>Upper limb passive mobilization assisted with robotic device | Device: Robotic passive mobilization<br>* The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forearm perfusion | Amount of total hemoglobin circulating in the forearm muscle tissues. | 30 minutes | 
| Muscle tone | The tone of the muscle assessed with Modified Ashworth Scale | 30 minutes |
DynaCT Imaging in EVAR: Comparing Clinical Benefit of DynaCT to Multidetector CT as the Current Gold Standard.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate a new way to create CT-like images during intra-operative procedures. We want to prove that the quality and information received from DynaCT is satisfactory in implementing stent-graft in abdominal aortic aneurysm.

Detailed Description
-----------------
The study will compare images from the new modality (DynaCT) with the present modality (Multi detectorCT). We make three different set of images from each modality.

Official Title
-----------------
Use of DynaCT in Endovascular Treatment of Abdominal Aortic Aneurysm. Evaluation of Image Quality.

Conditions
-----------------
Abdominal Aortic Aneurysm

Intervention / Treatment
-----------------
* Procedure: DynaCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 65, Satisfactory renal function

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: DynaCT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence og clinical benefit of new imaging functionality. |  | 3 days (pluss or minus 3 days). |
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine rates of oral and genital human papillomavirus (HPV) infections, and look at risk factors for HPV infection in healthy mid-adult women.

Detailed Description
-----------------
The investigators propose a longitudinal study of 500 women in order to determine rates and risk factors for HPV infections in 30-50 year old women. Participants will be followed for 6 months and will be asked to complete online questionnaires on their health, sexual behavior, HPV vaccinations, and cervical cancer screening. The investigators will ask participants to self-collect monthly vaginal swab samples and self-collect 2 oral swab samples. Women will also be asked to provide 2 blood samples. All swab samples will be tested for type-specific HPV deoxyribonucleic acid (DNA) using a polymerase chain reaction (PCR)-based assay, blood samples will be tested for HPV antibodies.

Official Title
-----------------
Natural History of HPV Infections in Mid-Adult Women

Conditions
-----------------
Papillomavirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: affiliated with the University of Washington (student, staff, faculty) willing to self-collect vaginal samples at home for HPV testing able to provide informed consent Exclusion Criteria: pregnant have had hysterectomy serious medical condition which prevents completion of activities of daily living

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of type-specific HPV DNA in self-collected oral and vaginal swab samples |  | once a month for 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, Cervical Cancer
Adherence Enhancement for Renal Transplant Patients

Study Overview
=================
Brief Summary
-----------------
Despite significant advances in the care of kidney transplant recipients, long term graft survival after renal transplantation remains suboptimal. Medication nonadherence and clinical inertia are key contributors to graft loss. The purpose of the proposed RCT feasibility study is to evaluate impact of a bundled wireless real time medication reminder system and blood pressure monitoring system in combination with a cognitive behavioral adherence skills enhancement program upon medication adherence, therapeutic drug concentration, and blood pressure, in nonadherent kidney transplant recipients with hypertension. We propose to recruit 60 kidney transplant recipients in phase 1 with 20 non-adherent continuing to phase 2 for a 5-month feasibility RCT.

Official Title
-----------------
Adherence Enhancement for Renal Transplant Patients

Conditions
-----------------
Renal Failure, Medication Adherence, Hypertension

Intervention / Treatment
-----------------
* Behavioral: mHealth


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons > 21 years of age first time recipient of a solitary kidney transplant prescribed at least 3 medications for immunosuppression and hypertension previous history of non-adherence functioning kidney transplant ability to speak, hear and understand English able to use medication delivery device and self administer medications able to operate blood pressure monitor comfortable using cell phone no other diagnosis that might shorten lifespan transplant physician's assent that the patient can participate Exclusion Criteria: failure to meet all inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Standard Care<br>Standard Care after kidney transplantation | |
| Experimental: mHealth<br>subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone. | Behavioral: mHealth<br>* mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| medication adherence | adherence to immunosuppressive medications | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure | resting blood pressure | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal failure, medication adherence, hypertension
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.

Official Title
-----------------
A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: natalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Male and female patients at least 18 years of age who have at least a six-month history of Crohn's disease and who are currently experiencing moderately to severely active Crohn's disease. Women must not be breastfeeding or pregnant, and must not become pregnant during the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: natalizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |